Betamed

Quick links to important sections

Betamed

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betamed

Quick Facts

Property Description
Active Ingredient Betaxolol Hydrochloride
Form Oral Tablets and Ophthalmic Preparations (Solution/Suspension)
Pharmacological Class Cardioselective Beta-blocker
General Purpose Pressure Modulator (Systemic and Ocular)
Origin Synthetic Compound

What is Betamed and How is it Classified?

Betamed is a prescription medication whose active component is Betaxolol Hydrochloride, a synthetic compound classified pharmacologically as a beta-blocker (beta-adrenergic receptor antagonist). This classification means the medicine works by moderating the impact of natural stress hormones, such as epinephrine (adrenaline), on the body. Betaxolol is specifically a cardioselective agent, focusing its action primarily on blocking the beta1 receptors found predominantly in the heart. Its role in cardiovascular regulation is recognized, reflecting the compound's established role in moderating cardiac activity.


Composition and Available Drug Forms

Betamed is a Single Product whose therapeutic action is derived entirely from its active ingredient, Betaxolol. This ingredient is made available in distinct high-level dosage form(s) for different delivery routes: an Oral Tablet formulated with a solid excipient matrix for systemic administration, and a sterile Ophthalmic Preparation (either a solution or suspension) carried in an aqueous vehicle for topical ocular administration. The availability of these distinct forms allows the pressure-modulating substance to be precisely directed to either the circulatory system via systemic absorption or the surface of the eye via topical application.


Betaxolol's General Pressure-Modulating Purpose

The general purpose of Betaxolol is to achieve pressure modulation by exerting a sympatholytic effect, which reduces nerve impulses from the sympathetic nervous system. In its oral form, the core benefit is to moderate the heart's activity, thereby helping to normalize systemic blood pressure. When used topically as an ophthalmic solution, the purpose shifts to decreasing the formation of fluid inside the eyeball, which serves to reduce intraocular pressure and alleviate strain on the eye's delicate internal structures. This dual applicability allows for pressure management through both systemic and direct ocular application.

What side effects are possible with Betamed?

Possible Side Effects and Safety Information

Betamed, a formulation containing a potent topical corticosteroid, carries a documented risk profile derived from regulatory documents for this class of medicine. The safety information addresses both localized application site reactions and the potential for systemic effects.

Adverse Reaction Category Common Local Reactions Potential Serious Systemic Risks
Adverse Reactions Stinging, burning, itching, irritation, skin dryness, folliculitis, acne, and skin atrophy (thinning). Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and allergic contact dermatitis.

HPA Axis Suppression and Systemic Effects

Systemic adverse reactions, such as HPA axis suppression (which can lead to adrenal insufficiency), are a clinically significant concern. The risk of these systemic effects, including manifestations of Cushing's syndrome, increases with prolonged use, application over large surface areas, or the use of occlusive dressings.

Population-Specific Safety

Pediatric patients are considered to be at greater risk for systemic toxicity, including HPA axis suppression and Cushing's syndrome, due to a higher ratio of skin surface area to body mass. Use in this population is generally limited to the minimum effective amount and duration.

Safety Restrictions and Monitoring

The product label includes restrictions on the total area and duration of application to mitigate systemic risks. Patients should be advised to report any signs of local irritation or allergic reactions, as discontinuation may be required. Furthermore, the development of visual symptoms necessitates an evaluation, as cataracts or glaucoma are documented risks associated with corticosteroid use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Betaxolol Hydrochloride (Betamed) primarily involves an exaggeration of the drug's effects on the cardiovascular, respiratory, and central nervous systems, as documented in official regulatory labeling.

Documented Manifestations and Severe Outcomes

System Documented Clinical Manifestations
Cardiovascular Bradycardia (slow heartbeat), Hypotension (low blood pressure), Heart Block, Overt Cardiac Failure, and Cardiogenic Shock.
Respiratory Bronchospasm, Dyspnea (difficulty breathing), and the risk of Respiratory Failure (particularly in sensitive individuals).
Central Nervous Dizziness, Confusion, Convulsions (seizures), and progression to Coma.

Overdose may lead to life-threatening outcomes, and while no specific antidote is known, management involves symptomatic and supportive treatment to stabilize documented signs of toxicity. For the topical ophthalmic form, the regulatory text notes the excess solution may be flushed from the eye(s) with warm water.

When to Seek Immediate Medical Help

Official guidance requires that emergency medical treatment must be sought immediately for any suspected overdose. Call emergency services right away if the individual has collapsed, had a seizure, has trouble breathing, or can't be awakened. Hypoglycemia (low blood sugar) is documented as a specific consideration common in overdose cases involving children.

Therapeutic Uses of Betamed

What Betamed Treats: Main Uses and Benefits

Betamed is applied across domains where additional symptomatic support is needed and is commonly used to help with symptomatic support during periods of heightened symptoms. It is relevant in areas where short-term symptom management is appropriate. It is used to assist with managing symptoms related to physical discomfort and inflammatory or irritative states.

The medicine is commonly used to help with symptom clusters that may become intense or disruptive and interfere with daily comfort. It is applied in addressing categories such as:

  • Symptoms related to physical discomfort (e.g., itching and redness).
  • Symptoms related to inflammatory or irritative states (e.g., swelling).
  • Symptoms of systemic imbalance that create noticeable physiological strain.

It may provide support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.


Support for Symptomatic Discomfort

This covers situations involving symptoms that create noticeable physiological strain and interfere with daily functioning. Betamed may assist with offering symptomatic relief that helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relevant for Symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Betamed?

Eligibility for Betamed (Betaxolol Hydrochloride) is determined by official governmental regulatory documents, which establish clear restrictions based on pre-existing conditions and population demographics.

Absolute Contraindications

Betamed is contraindicated and must not be used in patients with:

  • Cardiac Conditions: Sinus bradycardia, cardiogenic shock, overt cardiac failure, and heart block greater than first degree.
  • Respiratory Conditions: History of severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD).
  • Allergy: Known hypersensitivity to Betaxolol or any component.

Population and Condition-Based Restrictions

Use is restricted or requires caution in several groups:

Population/Condition Regulatory Status
Pediatric Patients (Oral Tablet) Safety and efficacy not established
Severe Renal Impairment Use is conditional, requiring a suggested reduced initial dosage
Pregnancy (FDA Category C) Not recommended unless potential benefit justifies potential fetal risk
Diabetes Mellitus Use with caution (may mask signs of hypoglycemia)
Older Adults (Oral Tablet) A reduced starting dosage is suggested

For the ophthalmic suspension (0.25%) formulation, safety and efficacy have been established in pediatric patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Betaxolol identifies several classes of products that may interact with the medicine, leading to changes in drug exposure or combined physiological effects.

Interaction Scope

Property Official Regulatory Documentation Summary
Medicinal product categories with documented interactions Other beta-adrenergic inhibitors (beta-blockers), Catecholamine-Depleting Drugs, Calcium Antagonists, Antiarrhythmics, CYP2D6 Inhibitors, Antacids, Ethanol (Alcohol).
Specific interacting medicines (if explicitly listed) Reserpine, Diltiazem, Verapamil, Amiodarone, Digoxin, Clonidine, Aluminum Hydroxide, Multivitamin with Minerals.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Synergism: Additive negative effects on heart rate/blood pressure. Inhibition of GI Absorption: Physical interference by agents like Antacids. Hepatic Enzyme Metabolism: Involvement of CYP2D6 in clearance.
Timing-based interaction rules (if applicable) Co-administration of oral Betaxolol with Multivitamin with Minerals or products containing Aluminum Hydroxide requires an at least 2-hour separation in administration time to mitigate reduced drug exposure.
Population-specific interaction notes (if applicable) Renal Impairment: Documented decrease in Betaxolol clearance, which may increase exposure. Elderly Patients: May be more susceptible to beta-blocker-induced bradycardia.

Official Interaction Statements

  • Co-administration with other oral beta-adrenergic blocking agents may result in documented additive systemic effects (e.g., bradycardia and hypotension).
  • Interaction with catecholamine-depleting drugs (e.g., Reserpine) is documented to produce possible additive effects, increasing the risk of hypotension and/or bradycardia.
  • Concomitant use with calcium antagonists (e.g., Diltiazem, Verapamil) or Digitalis Glycosides (e.g., Digoxin) may result in additive effects on cardiac function.
  • Administration of CYP2D6 inhibitors may increase Betaxolol plasma concentrations due to its involvement in the CYP2D6 metabolic pathway.
  • Interaction with Ethanol (alcohol) is documented to result in additive effects in lowering blood pressure, which may increase the risk of dizziness or fainting.

The official interaction profile is structured around managing the risk of pharmacodynamic reinforcement with other cardiovascular depressants and addressing pharmacokinetic modification through metabolism and reduced gastrointestinal absorption. Regulatory documents place constraints on co-administration, including mandatory timing rules for absorption-interfering agents.

Mechanism of Action

Mechanism of Action: Betaxolol Hydrochloride

Betaxolol functions as a beta1-adrenergic receptor (beta1-AR) antagonist, competitively blocking the binding site for endogenous catecholamines. This interaction produces distinct pharmacodynamic consequences based on the administration route.


Cardiovascular and Renal Sympathetic Inhibition

Systemically, Betaxolol inhibits beta1-ARs in cardiac tissue and the renal juxtaglomerular apparatus. Blockade in the myocardium dampens sympathetic drive, initiating a cascade that leads to reduced heart rate (chronotropy) and contractility (inotropy). The mechanism also decreases renin release from the kidney, which contributes to a reduction in systemic vascular pressure.


Modulation of Ocular Fluid Dynamics

Topically, beta1-AR antagonism occurs in the ciliary epithelium, suppressing the energy-dependent, active secretion of aqueous humor fluid. Inhibiting this secretory process causes a reduction in the internal fluid volume and pressure within the eyeball.


Secondary Neurocellular Stabilization

A distinct mechanism involves the drug's modulation of voltage-sensitive Ca^2+ and Na^+ channels in retinal neurons. This activity limits the excessive ion influx associated with excitotoxicity, resulting in the preservation of neuronal membrane potential.

Dosage and Administration Information

Betamed is administered using two distinct routes based on the intended site of action: Oral Tablets are taken for systemic effect, and Ophthalmic Preparations (solution or suspension) are applied topically for local effect.

Standardized Dosing and Frequency

The established oral regimen begins with a starting dose of 5 mg or 10 mg once daily. The dose may be increased, though the maximum recommended daily dose is 20 mg. Dose titration, if needed, should occur at intervals of 7 to 14 days to allow for a stable response to develop. For topical ocular administration, the standardized pattern is the instillation of one drop into the affected eye(s) twice daily.

Specific Usage Constraints

Specific instructions govern the use of the different forms. The ophthalmic suspension form must be shaken well immediately before each use. If using soft contact lenses, they must be removed prior to instillation and reinserted 15 minutes later.

Administration of other topical eye medications must be separated by at least 5 minutes. For specific populations, the oral initial starting dose for adults with severe renal impairment is explicitly set at 5 mg once daily. Standard practice for a missed dose indicates that the missed dose should be skipped entirely, and the normal dosing schedule should be resumed without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Betamed

Evidence for Managing Systemic Blood Pressure

Research has investigated the oral tablet form of Betaxolol in scenarios related to managing high blood pressure. Studies exploring this indication included Randomized, Double-Blind, Placebo-Controlled Trials (RCTs), dose-response studies, and comparative studies against other established agents. The main outcomes studied were related to BP measurements, including Systolic and Diastolic Blood Pressure (BP), and measured changes in Resting and Exercise Heart Rate (HR). Studies reported measurements of BP and HR that were recorded over the typical 24-hour dosing interval.

Evidence for Managing Intraocular Pressure

The research exploring Betaxolol for use in the eye included Randomized, Double-Masked, Controlled Studies comparing the substance against an inactive control or other topical agents used to manage pressure. The research primarily focused on measurements of Intraocular Pressure (IOP), measured in standard pressure units. Studies also monitored Visual Field parameters. Long-Term Observational Studies were also applied, with research describing measured IOP patterns that were consistent over periods of several years. Comparative evidence is available from studies that monitored IOP measurements relative to other topical agents.


Research Gaps and Patient Groups

The evidence for this compound is largely well-established across core adult populations. However, research exploring special populations, including older adults and patients with systemic or functional imbalance due to conditions like renal or hepatic impairment, has also been conducted, though data indicated patterns related to drug elimination that were not consistent across all research. Furthermore, the full research profile for pediatric subjects in the ocular setting is not fully established, as clinical studies to investigate the measurements in children have been limited in scope. In the systemic setting, long-term effects are not fully established when comparing outcomes to the use of combination therapies.

Key Studies & References

  1. Label: BETAXOLOL HYDROCHLORIDE tablet, coated - DailyMed (Oral Tablet Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Betamed (FAQ)


Q: Is Betamed considered a brand name medication?

A: Yes, Betamed is a brand name medication. The active ingredient in Betamed is Betaxolol Hydrochloride, which is also available under other brand names and as a generic version.

Regulatory information confirms that the active ingredient has been approved for use in generic versions by government bodies.


Q: Is there a lower-cost generic version of Betamed available?

A: Regulatory information confirms that generic versions of the active ingredient, Betaxolol, have been approved for use by government bodies.

However, the availability and cost of these generic versions may vary based on location and specific pharmacy stock.


Q: How is Betamed different from other medications used for the same condition?

A: Official documents describe Betamed as a cardioselective beta-blocker. This means that its primary mechanism of action targets the beta1 receptors, which are found mainly in the heart.

This selectivity is a key difference noted in the drug's classification when compared to non-selective agents.


Q: How long do people typically need to take Betamed?

A: For managing chronic conditions, such as high blood pressure, the oral form of this medicine may be required for long-term management.

The duration of use is determined by a healthcare provider based on the individual's condition and response to the treatment.


Q: Can taking Betamed cause weight changes or appetite issues?

A: According to official documents, both weight gain and weight loss are listed as possible adverse reactions. There are also reports of a lack of appetite being associated with the use of the drug.


Q: Is it possible for Betamed to cause sleep disturbances or insomnia?

A: Official product information states that insomnia is a reported adverse reaction. This refers to difficulty falling asleep or staying asleep.

Sleep disorders are also listed among the possible side effects of Betamed.


Q: What are the official warnings regarding Betamed and mood changes or anxiety?

A: The regulatory profile includes several psychiatric and central nervous system adverse reactions. These reported reactions include depression, anxiety, confusion, and abnormal thinking.


Q: What signs indicate a serious or severe adverse reaction to Betamed?

A: The official prescribing information lists the possibility of serious systemic effects. Serious systemic effects described in the label include signs related to cardiac function, such as sudden, unexplained weight gain or swelling of the limbs.

Additionally, individuals may experience difficulty breathing or a very slow, fast, or irregular heartbeat.


Q: Can Betamed interact with over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory guidance advises individuals to consult a healthcare provider regarding the use of nonprescription (over-the-counter) medicines. This includes common pain relievers.

Discussing this is important for managing potential interactions and ensuring safe use of Betamed.


Q: Are there any specific foods or supplements that should be avoided while taking Betamed?

A: Official prescribing information notes that certain products may interact with Betamed. For instance, co-administration with a Multivitamin with Minerals requires a 2 hour separation time.

Additionally, the drug profile notes that Potassium supplements and certain herbal remedies may interact with beta-blockers.


Q: Does Betamed have any reported interactions with herbal teas or remedies?

A: The official profile lists potential interactions between beta-blockers and certain herbal preparations.

These interactions may occur with herbal teas or remedies that contain cardiac glycosides, such as Pleurisy Root.


Q: Can I take Betamed if I am already on an antidepressant or anti-anxiety medicine?

A: Regulatory documents state that Betamed interacts with medicines that inhibit the CYP2D6 enzyme. Antidepressants and anti-anxiety medicines often fall into this category.

Official guidance suggests informing a healthcare provider about all other prescription medicines.


Q: Is Betamed considered safe for use while breastfeeding?

A: Official documents indicate that beta-blockers, including Betaxolol, are excreted in breast milk.

For this reason, caution is noted in the official guidance regarding administration to a nursing mother, due to the potential for serious undesirable effects in the infant.


Q: Do I need to inform my doctor about pre-existing health conditions before starting Betamed?

A: The prescribing information specifies that individuals are expected to inform their healthcare provider about certain pre-existing health conditions.

Individuals should also inform their care team about any planned surgeries, as the medicine may interact with anesthesia.


Q: Is Betamed appropriate for people with a history of kidney or liver problems?

A: Official documents note that dosage adjustments are typically necessary for individuals with severe renal impairment (kidney issues).

However, official information regarding specific dosing adjustments for patients with liver problems is less defined in regulatory texts.


Q: What kind of routine monitoring tests might be needed while taking Betamed?

A: The prescribing information advises that a healthcare professional will check progress at regular visits. This routine monitoring is intended to ensure the medicine is working properly.

Monitoring may involve assessing changes in heart rate, blood sugar, or signs suggestive of heart failure.


Q: Are there different formulations of Betamed (e.g., immediate-release vs. extended-release)?

A: Betamed is available as an oral tablet and as an ophthalmic preparation. The oral tablet is typically prescribed for once-daily use.

However, the official documents do not explicitly state if the oral tablet is an immediate-release or extended-release formulation.


Q: Can Betamed cause sensitivity to sunlight or a skin rash?

A: The regulatory profile lists skin rash as a reported adverse reaction.

For the ophthalmic form, increased sensitivity of the eyes to sunlight has also been reported in official documents.


Q: Does Betamed cause drowsiness that affects driving or operating machinery?

A: The official prescribing information indicates that Betamed may cause drowsiness or temporary blurred vision.

Official guidance indicates that individuals should assess how the medication affects them before engaging in activities like driving or operating machinery.


Q: What is the risk of dependency or withdrawal symptoms when discontinuing Betamed?

A: Regulatory warnings discourage abruptly stopping Betamed, especially for individuals with known coronary artery disease.

This is due to the risk of exacerbation of angina pectoris (chest pain), and in some cases, sudden withdrawal may lead to myocardial infarction (heart attack).


Q: What information is available about Betamed's effect on fertility?

A: Regulatory summaries note that animal studies showed reproductive toxicity when the drug was administered.

Official information indicates that there are no adequate and well-controlled studies regarding the effects of Betamed on human fertility.

How should Betamed be stored and disposed of?

Storage Conditions

Betamed (Betaxolol Hydrochloride) must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F). The medication must be actively protected from freezing, excessive heat, moisture, and light. Official labeling requires storing the product in its tightly closed, original container.

Dosage Form Mandatory Requirement
All Forms Keep out of the sight and reach of children.
Ophthalmic Forms Avoid touching the dropper tip to any surface.
Ophthalmic Solution Discard the bottle 28 days after opening.

Disposal

Outdated or unused Betamed must not be kept. Patients are instructed to consult a healthcare professional regarding the proper method for disposing of any medicine they no longer need, ensuring it adheres to pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betamed found in:

A-Z Index: